Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 26, 2024. 

NeurologyLive® Friday 5 — April 26, 2024

Videos

The associate professor of neurology at Harvard Medical School discussed findings from a study investigating nasal foralumab in patients with non-active secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]

Potential of Nasal Foralumab in Treating Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS

Stephen Samples, MD, chair of Allegheny Health Network’s department of neurology, gave commentary towards the AHS’s recent statement paper addressing CGRP-targeting therapies as a first-line option for preventive migraine.

Expanding Access to CGRP Medications as First-Line Treatments: Thoughts and Implications

The neuropsychologist and assistant professor of neurology at the University of California, San Francisco Memory and Aging Center provided comment on her presentation from AAN 2024 examining the association of area deprivation index with cognitive functioning in Black women. [WATCH TIME: 3 minutes]

Understanding the Cognitive Impact of Neighborhood Disadvantage on Black Women: Tanisha Hill-Jarrett, PhD

, has been with the team since October 2019. Follow him on Twitter 

Associate professor of chemistry at Vanderbilt University and the inaugural Dorothy J. Wingfield Phillips Chancellor’s Faculty Fellow.

The associate professor of chemistry at Vanderbilt University talked about research surrounding racial and ethnic disparities in Alzheimer disease incidence. [WATCH TIME: 5 minutes]

Insights on Addressing Disparities in Alzheimer Disease Research: Renã A. S. Robinson, PhD

The professor of neurology at the NYU Grossman School of Medicine provided commentary on a study that demonstrated the benefits of using tDCS along with sleep language training to promote naming in primary progressive aphasia. [WATCH TIME: 5 minutes]

Therapeutic Potential of Transcranial Direct Current Stimulation in Primary Progressive Aphasia: Leigh Charvet, PhD

The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center provided commentary on the need to properly diagnose Lennox-Gastaut syndrome and the negative downstream impacts of misdiagnosis or underdiagnosing patients.

NeuroVoices: Scott Perry, MD, on the Intricacies and Value of Diagnosing Lennox-Gastaut Syndrome

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Advances in the Management of Excessive Daytime Sleepiness and Narcolepsy

In this program, sleep experts will discuss the importance of timely and accurate diagnosis, recent approvals and available treatment options for the management of narcolepsy and excessive daytime sleepiness.

Experts provide an overview of excessive daytime sleepiness and narcolepsy.

Narcolepsy  Overview 

Anne Marie Morse, DO, FAASM, discusses the burden and risk factors associated with excessive daytime sleepiness and narcolepsy.

Burden and Risk Factor of Narcolepsy

Experts discuss narcolepsy diagnosis and the challenges associated with it.

Diagnosis of Narcolepsy

Thomas E. Scammell, MD, discusses evaluating excessive daytime sleepiness (EDS).

EDS Evaluation 

Debra Stultz, MD, provides an overview of the available resources that are available for narcolepsy treatment.

Available Resources for Narcolepsy Treatment

Neurology experts describe the goals of therapy for narcolepsy treatment. 

Goals of Therapy for Narcolepsy 

Karl Doghramji, MD, FAASM, DFAPA, provides an overview of the pharmacological treatment options for narcolepsy.

Pharmacological Treatment Options for Narcolepsy

Neurology experts discuss excessive daytime sleepiness (EDS) and narcolepsy treatment options. 

EDS and Narcolepsy Treatment Options

Thomas E. Scammell, MD, provides an overview of the mechanism of action of pitolisant for the treatment of narcolepsy.

Pitolisant: Mechanism of Action

Anne Marie Morse, DO, FAASM, discusses the efficacy and safety profile of pitolisant for the treatment of narcolepsy.

Pitolisant Efficacy and Safety

Experts discuss the efficacy and safety profile of solriamfetol for the treatment of narcolepsy.

Solriamfetol Efficacy and Safety

Experts discuss sodium oxybate and antidepressants for treatment of cataplexy.

Sodium Oxybate and Antidepressants for Treatment of Cataplexy 

Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences. 

Unmet Needs in Narcolepsy and Clinical Pearls

Peer Exchange

Clinical

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Goals of Therapy for Narcolepsy

EP: 1.Narcolepsy Overview

EP: 2.Burden and Risk Factor of Narcolepsy

EP: 3.Diagnosis of Narcolepsy

EP: 4.EDS Evaluation

EP: 5.Available Resources for Narcolepsy Treatment

EP: 6.Goals of Therapy for Narcolepsy

EP: 7.Pharmacological Treatment Options for Narcolepsy

EP: 8.EDS and Narcolepsy Treatment Options

EP: 9.Pitolisant: Mechanism of Action

EP: 10.Pitolisant Efficacy and Safety

EP: 11.Solriamfetol Efficacy and Safety

EP: 12.Sodium Oxybate and Antidepressants for Treatment of Cataplexy

EP: 13.Unmet Needs in Narcolepsy and Clinical Pearls